MedTrace Logo

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

NCT02707328 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-07-30

No results posted yet for this study

Summary

This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.

Conditions

  • Pancreas Cancer
  • Pancreatic Cancer
  • Adenocarcinoma of the Pancreas
  • Pancreas Adenocarcinoma
  • Pancreatic Adenocarcinoma

Interventions

DRUG

Gemcitabine

DRUG

nab-paclitaxel

RADIATION

CyberKnife

Sponsors & Collaborators

  • The Cooper Health System

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-11-10
Completion
2017-11-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02707328 on ClinicalTrials.gov